The multibillion-dollar commitment announced Monday, which is “one of the largest production investments in Novo Nordisk’s history,” according to the pharmaceutical company, will fund the construction of an instant fill and fill facility in Clayton, North Carolina.
The new plant will add 1. 4 million feet of production area to Novo’s footprint in the U. S. The U. S. Department of Homeland Security has been able to expand on the combined footage of its three existing locations in North Carolina. The new filling and finishing plant will be capable of aseptic and finished production processes and will create 1,000 new jobs in the state.
Monday’s investment comes as Novo plans to increase its production investment to $6. 8 billion in 2024, up from $3. 9 billion last year.
Novo CEO Lars Fruergaard Jørgensen called Monday’s investment “a genuine signal” of the pharmaceutical company’s “efforts to ramp up our production and meet the growing global need for our life-changing medicines. “
The North Carolina facility is expected to be completed between 2027 and 2029 and will employ approximately 2,000 outside contractors. Deforestation and painting of the plant’s bases are already underway.
The $4. 1 billion investment announced Monday is the latest development in Novo’s efforts in recent months to expand its production functions and address the market’s insatiable appetite for its successful GLP-1 receptor agonist, semaglutide, billed as Ozempic for type 2 diabetes and Wegovy for chronic diabetes. weight control.
In November 2023, Novo announced a $6 billion commitment to its operations in Denmark, primarily to meet existing and long-term demand for its medicines. The pharmaceutical company announced the investment with a capital tranche of $3. 6 billion last year and will supply the remaining amount. over the next six years.
In February 2024, Novo’s parent company, the Novo Nordisk Foundation, acquired CDMO Catalent for $16. 5 billion. Subsequently, the foundation’s investment arm, Novo Holdings, announced that it would sell 3 of Catalent’s filling and finishing sites to the pharmaceutical industry.
A month later, Novo announced a $556 million commitment to China, which will build a sterile compounding plant to increase supply.
Tristan Manalac is an independent scientist founded in Metro Manila, Philippines. Connect with them on LinkedIn or email them at tristan@tristanmanalac. com or tristan. manalac@biospace. com.
Back to news